Quarterly results round-up: Beckman still strong overall, as Gen-Probe misses expectations
This article was originally published in Clinica
Executive Summary
Beckman Coulter reported third-quarter revenue of $893.8m, which was up by around 9% compared to the same period last year. The growth was attributed, in part, to the acquired Olympus lab-based diagnostics division. The acquisition helped to considerably bulk up Beckman's chemistry and clinical automation business, which recorded 14% reported growth in sales, at $323.2m. This, in turn, helped to drive, clinical diagnostics revenue, which reached $787.6m (11% reported growth). Geographically, strong sales in Asia-Pacific and emerging markets helped to off-set softness in developed markets. Beckman’s net income for the period was $67m, a significant improvement on Q3 2009 which was impacted by $79.2m in restructuring charges and reported earnings of $1.5m.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals